Navigation Links
New Data Presented at AUA's Annual Conference Prove GELNIQUE(TM) (oxybutynin chloride) 10% gel is an Effective, Safe Option for Female Overactive Bladder (OAB) Patients
Date:4/27/2009

- First and Only Topical Gel for OAB to Launch in U.S. Next Month -

CHICAGO, April 27 /PRNewswire-FirstCall/ -- Data to be presented at the American Urological Association's (AUA) Annual Conference show that GELNIQUE(TM) (oxybutynin chloride) 10% gel significantly improves symptoms of OAB and urinary urge incontinence in women with the condition. By the end of the 12-week study period, 27 percent of women treated with GELNIQUE achieved complete urinary continence versus 15.6 percent treated with placebo. There were no treatment-related serious adverse events.

GELNIQUE, the first and only topical gel for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and frequency, is a quick drying, clear and colorless, fragrance-free gel containing oxybutynin hydrochloride that is developed and marketed by Watson Pharmaceuticals, a leader in generic and specialty branded pharmaceuticals. The gel received approval from the U.S. Food and Drug Administration in January 2009 and will launch mid-May.

"Women suffering from OAB often experience severe symptoms at a younger age, so it's important that we have an effective treatment that is both well tolerated and convenient for our female patients," said Roger R. Dmochowski, M.D., professor of urologic surgery at Vanderbilt University Medical Center and director of the Vanderbilt Continence Center, in Nashville, who presented the new findings. "Our new data further confirm that for women with OAB, GELNIQUE is a novel treatment approach with strong efficacy and excellent tolerability."

OAB is characterized by a sudden, uncomfortable need to urinate with or without urge incontinence (urine leakage), and usually includes more frequent urination and nocturia (waking up more than once during the night to urinate). It affects as many as 34 million adults in the U.S. - more than diabetes or asthma. The U.S. OAB market currently
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. NKTR-105 Demonstrates Superior Antitumor Activity and Improved Pharmacokinetics Over Docetaxel in Preclinical Studies Presented at AACR
2. Mersanas Second Development Candidate, XMT-1107, Shows Superior Pharmacokinetics and Anti-Tumor Activity in Studies Presented at American Association of Cancer Research Meeting
3. Altrazeal(TM) Clinical Evidence to be Presented at The American Professional Wound Care Association (APWCA) National Clinical Conference 2009
4. 2009 ESCEO-IOF Alliance for Better Bone Health Young Investigator Award presented to Dr. Nick Harvey
5. IADR Oral Medicine and Pathology Research Award presented to UCLA professor
6. Prizes of the Grand Prix MSOO Award Presented in Moscow
7. Pasadena Marathon Presented By Kaiser Permanente Hails Partnership With Tiffany & Co.
8. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Extended Release (ER) Phase 3 Clinical Data Presented at World Institute of Pain 5th Annual World Congress
9. Destination Fashion 2009 Presented by Stewart Rahr -
10. NovaBay Pharmaceuticals Announces New Preclinical Data to be Presented at the American Academy of Dermatology (AAD) 67th Annual Meeting
11. Crossflo Health Information Exchange Project Presented at HP Health and Life Sciences Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... 2015 The PracticeMatch Career Fair ... 8:00 pm at the Sheraton Colonial Boston North Hotel, 1 ... and groups with career opportunities will be attending from across ... free hors d’oeuvres and raffle prize drawings. , Leslie Thompson, ... is an ideal location to hold a career fair. In ...
(Date:4/28/2015)... April 28, 2015 The Awareness Counselor team ... common topic of judging. According to Awareness Counselor, there are ... when directed outward, and to an individual who self-judges. This ... clients as a class or one one one talk. , ... of Awareness Counselor, is that every being on earth is ...
(Date:4/28/2015)... Aliso Viejo, CA (PRWEB) April 28, 2015 ... created for use in Final Cut Pro X ... attention to specific areas on-screen with classic buttons, animated ... Annotate is the perfect compliment to vlogs, video series, ... Cut Pro X 10.2 or newer. ProTube Annotate ...
(Date:4/28/2015)... PREVENT Life Safety, Inc., America’s premier provider ... their Southern California offices from Orange, California to Rancho ... I (letter I), Rancho Cucamonga, CA, 91730, is effective ... the significant growth the company has realized in the ... to provide superior life safety services, including fire damper ...
(Date:4/27/2015)... 2015 Medical Device Design Control , ... Ombu Enterprises**, June 16-17, 2015 – Chicago, IL , ... to a facility today, would the design control system ... is "maybe" or "no" … then very likely there ... a solution. , Take this important step. Enroll ...
Breaking Medicine News(10 mins):Health News:PracticeMatch to Host Physician Career Fair at Sheraton Colonial Boston North Hotel on May 6, 2015 2Health News:PracticeMatch to Host Physician Career Fair at Sheraton Colonial Boston North Hotel on May 6, 2015 3Health News:What Happens When We Judge Ourselves and Others? – A New Concept Introduced 2Health News:What Happens When We Judge Ourselves and Others? – A New Concept Introduced 3Health News:FCPX plugin developer Pixel Film Studios releases Protube Annotate plugin for Final Cut Pro X. 2Health News:PREVENT Life Safety Moves to New Office in Rancho Cucamonga 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 3Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 4
... smokers twice as likely to have strokes, they are almost ... to a study presented today at the Canadian Stroke Congress. ... stroke patients (264 smokers and 718 non-smokers) at an Ottawa ... who smoked was 58, compared to age 67 for non-smokers. ...
... in South Africa and Brazil become happier as they age. ... a developing country can significantly improve the wellbeing of its ... older people in South Africa and Brazil improved between 2002 ... enlightened social policies, according to a study from the New ...
... By Amanda Gardner HealthDay Reporter , FRIDAY, ... United States, which reached a record high last year, are ... So far this year, some 200 drug shortages have ... Jensen, associate director of the Drug Shortage Program within the ...
... using a 320 detector row CT scanner found that a ... sufficient enhancement in more than 96% of coronary segments," said ... and one of the authors of the study. ... equal to 80 milliliters of iopamidol," he said. The ...
... such as depression, obsessive-compulsive disorder or anxiety states ... of the neurotransmitter serotonin. Neurotransmitters are compounds that ... endings and activate the firing of neighboring neurons. ... transmission of nerve impulses. The serotonin transporter (SERT) ...
... women experience peer pressure to share sexual images via the ... Melbourne study has found. ,Sexting, is the practice of ... The study is one of the first academic investigations ... findings were presented to the 2011 Australasian Sexual Health Conference ...
Cached Medicine News:Health News:Smoking causes stroke to occur 2Health News:Older people are happier in Brazil and South Africa 2Health News:Drug Shortages Even Worse This Year: FDA 2Health News:Combating mood disorders 2Health News:'Sexting' driven by peer pressure 2
(Date:4/28/2015)... and INDIANAPOLIS , April 28, 2015 /PRNewswire/ ... procedure and receive a heart stent are prescribed an oral ... attack, a blood clot in their heart stent (stent thrombosis), ... Poll found that 52 percent of 275 ACS patients who ... the way they take their prescribed OAP therapy, even though ...
(Date:4/28/2015)... We are living a connected life in a ... and very soon we will be able to connect our ... life market has been valued by Frost & Sullivan at ... drive and manage this change to stay ahead of the ... Highlights of the congress include a groundbreaking keynote address showcasing ...
(Date:4/27/2015)... April 27, 2015 A  study published today ... and presented at the annual Pediatric Academic Societies ... of rapid whole-genome sequencing in neonatal and pediatric intensive ... STAT-Seq test helped diagnose a genetic disease in more ... compared to just nine percent with standard genetic tests. ...
Breaking Medicine Technology:Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 2Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 3Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 4Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 5Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 6Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 7Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 8Survey Finds Half of Heart Stent Patients Don't Take Their Oral Antiplatelet Medication As Prescribed 9Frost & Sullivan's GIL 2015 Unveils the $700 Billion Connected Life Market 2Frost & Sullivan's GIL 2015 Unveils the $700 Billion Connected Life Market 3Study Demonstrates Potential Of Rapid Whole-Genome Sequencing In Critically Ill Infants 2Study Demonstrates Potential Of Rapid Whole-Genome Sequencing In Critically Ill Infants 3
... 2011 Merz Pharmaceuticals today announced the launch of ... their treatment with Xeomin® (incobotulinumtoxinA). XEOMIN is a botulinum ... approved by the U.S. Food and Drug Administration (FDA) ... decrease the severity of abnormal head position and neck ...
... HILLS, Ill., March 8, 2011 Genus Oncology, LLC, a ... cancer, announced it has received an Orphan Drug Designation from ... 1 (MUC1) targeting peptide, GO-203-2c, for the treatment of pancreatic ... the US Orphan Drug Act, is for a product that ...
Cached Medicine Technology:Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA) 2Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA) 3Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA) 4Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA) 5Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA) 6Genus Oncology, LLC Announces Orphan Drug Status for GO-203-2c for Treatment of Pancreatic Cancer 2
MP-250N and 300N is a new style power supply. It is a versatile microprocessor power supply for horizontal or vertical gel electrophoresis. The unit is programmable and offers constant voltage and co...
... ZOOM® Dual Power is a microprocessor-controlled ... both high voltage/low current and high ... voltage/low current section is ideal for ... DNA sequencing applications. The low voltage/high ...
... Power Supply is designed specifically ... extensive programming capabilities including eight ... for you to set to ... intuitive PowerEase interface is faster ...
PS2A200 Power supply is a high current power supply ideal for all types of electrophoresis blotting and short electrophoresis runs....
Medicine Products: